Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients

Irit Avivi, Yael C. Cohen, Anna Suska, Tamir Shragai, G. Mikala, Laurent Garderet, Gueye M. Seny, Sophia Glickman, David S. Jayabalan, Ruben Niesvizky, Alessandro Gozzetti, Katarzyna Wiśniewska-Piąty, Anna Waszczuk-Gajda, Lidia Usnarska-Zubkiewicz, Iwona Hus, Renata Guzicka, Jakub Radocha, Vibor Milunovic, Julio Davila, Massimo GentileJorge J. Castillo, Artur Jurczyszyn

Research output: Contribution to journalArticle

1 Citation (Scopus)


The current study assesses the characteristics and outcomes of multiple myeloma (MM) patients, treated with novel agents for hematogenous extramedullary (HEMM) relapse. Consecutive patients diagnosed with HEMM between 2010-2018 were included. Patients' characteristics at diagnosis and at HEMM presentation, response to treatment, survival and factors predicting survival were recorded and analyzed. A group of 127 patients, all diagnosed with HEMM by imaging (87.3%) and/or biopsy (79%), were included. Of those, 44% were initially diagnosed with ISS3, 57% presented with plasmacytomas, and 30% had high-risk cytogenetics. Median time to HEMM was 32 months. In multivariate analysis, ISS3 and bone plasmacytoma predicted shorter time to HEMM (P =.005 and P =.008, respectively). Upfront autograft was associated with longer time to HEMM (P =.002). At HEMM, 32% of patients had no BM plasmacytosis, 20% had non-secretory disease and 43% had light-chain disease. Multiple HEMM sites were reported in 52% of patients, mostly involving soft tissue, skin (29%), and pleura/lung (25%). First treatment for HEMM included proteasome inhibitors (50%), immunomodulatory drugs (IMiDs) (39%), monoclonal antibodies (10%), and chemotherapy (53%). Overall response rate (ORR) was 57%. IMiDs were associated with higher ORR (HR 2.2, 95% CI 1.02-4.7, P =.04). Median survival from HEMM was 6 months (CI 95% 4.8-7.2). Failure to achieve ≥VGPR was the only significant factor for worse OS in multivariate analyses (HR = 9.87, CI 95% 2.35 - 39, P =.001). In conclusion, HEMM occurs within 3 years of initial myeloma diagnosis and is associated with dismal outcome. The IMiDs might provide a higher response rate, and achievement of ≥VGPR predicts longer survival.

Original languageEnglish
JournalAmerican Journal of Hematology
Publication statusPublished - Jan 1 2019

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients'. Together they form a unique fingerprint.

  • Cite this

    Avivi, I., Cohen, Y. C., Suska, A., Shragai, T., Mikala, G., Garderet, L., Seny, G. M., Glickman, S., Jayabalan, D. S., Niesvizky, R., Gozzetti, A., Wiśniewska-Piąty, K., Waszczuk-Gajda, A., Usnarska-Zubkiewicz, L., Hus, I., Guzicka, R., Radocha, J., Milunovic, V., Davila, J., ... Jurczyszyn, A. (2019). Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients. American Journal of Hematology. https://doi.org/10.1002/ajh.25579